申请人:Achillion Pharmaceuticals, Inc.
公开号:EP2374812A2
公开(公告)日:2011-10-12
The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I
and the pharmaceutically salts and hydrates thereof.
The variables R1-R9, R16, R18, R19, n, M, , n, M, , and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/ or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
本发明提供了式 I 的 4-氨基-4-氧代丁酰基肽化合物
及其药用盐和水合物。
变量 R1-R9、R16、R18、R19、n、M、、n、M、和 Z 在本文中定义。某些式 I 化合物可用作抗病毒剂。本文公开的某些 4-氨基-4-氧代丁酰基肽化合物是病毒复制,特别是丙型肝炎病毒复制的强效和/或选择性抑制剂。本发明还提供了含有一种或多种 4-氨基-4-氧代丁酰基肽化合物和一种或多种药学上可接受的载体的药物组合物。这种药物组合物可以含有4-氨基-4-氧代丁酰基肽化合物作为唯一的活性剂,也可以含有含4-氨基-4-氧代丁酰基肽化合物和一种或多种其他药物活性剂的组合。本发明还提供了治疗哺乳动物病毒感染(包括丙型肝炎感染)的方法。